109 related articles for article (PubMed ID: 10669190)
1. Hydroxyurea in the treatment of HIV-1.
Gibbs MA; Sorensen SJ
Ann Pharmacother; 2000 Jan; 34(1):89-93. PubMed ID: 10669190
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea as part of a salvage regimen for heavily pretreated patients with advanced HIV infection.
Grunke M; Dechant C; Löw P; Rascu A; Kalden JR; Harrer T
J Acquir Immune Defic Syndr; 1999 Aug; 21(5):424-6. PubMed ID: 10458626
[No Abstract] [Full Text] [Related]
3. Is Hydroxyurea for real?
Mascolini M
J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):6-16, 18. PubMed ID: 11365731
[TBL] [Abstract][Full Text] [Related]
4. [Hydroxyurea and HIV infection].
Nkoghe D; Kola L; Léonard P; Demonty J; Moutschen M
Rev Med Liege; 2000 Jul; 55(7):721-4. PubMed ID: 11014107
[TBL] [Abstract][Full Text] [Related]
5. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide.
Vila J; Nugier F; Barguès G; Vallet T; Peyramond D; Hamedi-Sangsari F; Seigneurin JM
Lancet; 1997 Aug; 350(9078):635-6. PubMed ID: 9288048
[No Abstract] [Full Text] [Related]
6. Clinical use of hydroxyurea in HIV-1 infected patients.
Frank I
J Biol Regul Homeost Agents; 1999; 13(3):186-91. PubMed ID: 10560754
[TBL] [Abstract][Full Text] [Related]
7. Role of immune modulation in primary HIV infection.
Lori F; Lisziewicz J
J Biol Regul Homeost Agents; 2000; 14(1):45-8. PubMed ID: 10763893
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).
Stebbing J; Nelson M; Orkin C; Mandalia S; Bower M; Pozniak A; Gazzard B
J Antimicrob Chemother; 2004 Mar; 53(3):501-5. PubMed ID: 14762056
[TBL] [Abstract][Full Text] [Related]
9. Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.
Frank I; Bosch RJ; Fiscus S; Valentine F; Flexner C; Segal Y; Ruan P; Gulick R; Wood K; Estep S; Fox L; Nevin T; Stevens M; Eron JJ;
AIDS Res Hum Retroviruses; 2004 Sep; 20(9):916-26. PubMed ID: 15597521
[TBL] [Abstract][Full Text] [Related]
10. Role of hydroxyurea in treatment of disease due to human immunodeficiency virus infection.
Zala C; Rouleau D; Montaner JS
Clin Infect Dis; 2000 Jun; 30 Suppl 2():S143-50. PubMed ID: 10860899
[TBL] [Abstract][Full Text] [Related]
11. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network.
Hellinger JA; Iwane MK; Smith JJ; Fleishman AN; Torres RA; Schrader S; Perez G; Cohen CJ; Skowron G; Giordano MF; Accetta G; Cooper EC; Frost KR
J Infect Dis; 2000 Feb; 181(2):540-7. PubMed ID: 10669337
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.
Lori F; Rosenberg E; Lieberman J; Foli A; Maserati R; Seminari E; Alberici F; Walker B; Lisziewicz J
AIDS Res Hum Retroviruses; 1999 Oct; 15(15):1333-8. PubMed ID: 10515148
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea and HIV: 5 years later--from antiviral to immune-modulating effects.
Lori F
AIDS; 1999 Aug; 13(12):1433-42. PubMed ID: 10465065
[No Abstract] [Full Text] [Related]
14. Hydroxyurea-induced nail pigmentation in HIV patients.
Joyner S; Lee D; Hay P; Lau R
HIV Med; 1999 Oct; 1(1):40-2. PubMed ID: 11737328
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of hydroxyurea.
Gwilt PR; Tracewell WG
Clin Pharmacokinet; 1998 May; 34(5):347-58. PubMed ID: 9592619
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea and HIV-1 viraemia.
Lafeuillade A; Pellegrino P; Poggi C; Profizi N; Thiebaut C
AIDS; 1995 Nov; 9(11):1290-1. PubMed ID: 8561988
[No Abstract] [Full Text] [Related]
17. Hydroxychloroquine+ddI+Hydroxyurea antiretroviral trial, AIDS Research Alliance, Los Angeles.
AIDS Treat News; 1999 Dec; (No 332):8. PubMed ID: 11367131
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.
Montaner JS; Mo T; Raboud JM; Rae S; Alexander CS; Zala C; Rouleau D; Harrigan PR
J Infect Dis; 2000 Feb; 181(2):729-32. PubMed ID: 10669364
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea-induced neurotoxicity in HIV disease.
Barry M; Clarke S; Mulcahy F; Back D
AIDS; 1999 Aug; 13(12):1592-4. PubMed ID: 10465092
[No Abstract] [Full Text] [Related]
20. Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects.
Lori F; Lisziewicz J
Antivir Ther; 1999; 4 Suppl 3():101-8. PubMed ID: 16021881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
